Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target Following Major Licensing Agreement

Core Viewpoint - Emerging Growth Research reaffirms a Buy-Emerging rating for OSR Holdings, Inc. with a 12-month price target of $10.00, indicating a potential upside of approximately 1,487% from the closing price of $0.63 on December 3, 2025 [2][3]. Licensing Agreement - OSR Holdings has announced a major non-binding licensing term sheet with BCM Europe AG valued at $815 million for the global development and commercialization of VXM01, an oral T-cell immunotherapy program [3][6]. - The agreement includes an initial upfront payment of $20 million expected in 2026, along with significant milestone payments [6]. Strategic Implications - The licensing agreement is seen as a significant milestone for OSR Holdings, validating the management's strategic vision and execution capabilities [3][6]. - The likelihood of completing a definitive licensing agreement has increased due to BCME's formation of a fund structure and accelerated exclusivity timelines [6]. Financial Outlook - The licensing deal is expected to generate meaningful cash flow starting in 2026, addressing previous investor concerns regarding cash burn and share dilution [6]. - The potential expansion of the BCME partnership to include additional oncology assets could provide further valuation upside through a multi-asset licensing structure [6]. Market Recovery - OSR Holdings shares have recovered from early 2025 lows caused by market maker disputes and other issues unrelated to the company's fundamentals, but they remain heavily discounted relative to their intrinsic value [6].